Compare RMT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | FDMT |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.7M | 695.3M |
| IPO Year | N/A | 2019 |
| Metric | RMT | FDMT |
|---|---|---|
| Price | $14.17 | $15.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.71 |
| AVG Volume (30 Days) | 111.6K | ★ 846.4K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | $9.42 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $9.52 | $5.97 |
| 52 Week High | $14.78 | $16.93 |
| Indicator | RMT | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 70.35 |
| Support Level | $13.68 | $8.68 |
| Resistance Level | $14.35 | N/A |
| Average True Range (ATR) | 0.21 | 1.02 |
| MACD | -0.01 | 0.59 |
| Stochastic Oscillator | 29.29 | 79.48 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).